TY  - CHAP
M1  - Book, Section
TI  - Cancer
A1  - Papadakis, Maxine A.
A1  - McPhee, Stephen J.
A1  - Rabow, Michael W.
A1  - McQuaid, Kenneth R.
PY  - 2022
T2  - Current Medical Diagnosis & Treatment 2022
AB  - ROS1-rearranged  lung  cancers  respond  to  crizotinib  (ALK,  cMET,  and  ROS1  tyrosine  kinase  inhibitor)  and  entrectinib  (multikinase  inhibitor,  including  ROS-1)  with  response  rates  over  70%.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1183884699
ER  -